Symbiotec Pharmalab IPO
Bookbuilding IPO | ₹1,757.00 Cr | Listing at BSE, NSE
Closed
IPO Open
Mon, Aug 24, 2026
IPO Close
Thu, Aug 27, 2026
Price Band
₹938.00 to ₹988.00
Market Cap (Pre-IPO)
₹6,244.43 Cr
IPO Details
| IPO Date | Aug 24, 2026 to Aug 27, 2026 |
| Listing Date | Tentative: Sep 01, 2026 |
| Face Value | ₹2.00 per share |
| Price Band | ₹938.00 to ₹988.00 |
| Lot Size | 15 Shares (Minimum: ₹14,820.00) |
| Sale Type | Offer For Sale + Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹1,757.00 Crores |
| Total Shares Offered | 17,786,442 shares |
| Fresh Issue | 1,521,261 shares |
| Offer For Sale | 16,265,181 shares |
Subscription Data
| Category | Times Subscribed |
|---|---|
| QIB | 181.20x |
| NII | 77.56x |
| RII | 13.69x |
| Total | 75.08x |
Symbiotec Pharmalab IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 50.00 |
| Retail Shares Offered | 35.00 |
| NII Shares Offered | 15.00 |
Symbiotec Pharmalab IPO Lot Size
Investors can bid for a minimum of 15 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹192,660 |
| S-HNI (Min) | 14 | 210 | ₹207,480 |
| S-HNI (Max) | 67 | 1,005 | ₹992,940 |
| B-HNI (Min) | 68 | 1,020 | ₹1,007,760 |
Symbiotec Pharmalab Financial Information (Restated Consolidated)
Symbiotec Pharmalab Ltd.'s revenue increased by 15% and profit after tax (PAT) rose by 14% between the financial year ending with March 31, 2026 and March 31, 2025.
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Amount in ₹ Cr
Key Performance Indicators
As of Tuesday, March 31, 2026| KPI | Values |
|---|---|
| ROE (Return on Equity) | 11.19% |
| ROCE (Return on Capital Employed) | 11.56% |
| RoNW (Return on Net Worth) | 9.48% |
| PAT Margin (Profit After Tax Margin) | 12.60% |
| EBITDA Margin | 26.59% |
| Price to Book Value | 5.35 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 17.82 | 17.39 |
| P/E (x) | 55.44 | 56.81 |
Company Overview
Symbiotec Pharmalab Ltd. – Company Overview
- Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), nutritional ingredients, and specialty products.
- The company serves domestic and international markets, catering to both regulated and emerging regions.
- The company has over 30 years of industry experience and has evolved from a lab-scale steroidal hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform.
- Symbiotec Pharmalab has received approvals and certifications from regulatory bodies including US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea, along with other global regulatory organisations.
- As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities, with a maximum chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 KL.
- The company focuses on research-driven manufacturing, quality compliance, and sustainable production, supporting the pharmaceutical, nutraceutical, and wellness industries with ingredients aligned with global standards.
Company Strengths
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
- Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Use of Proceeds
| 1) | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| 2) | General corporate purposes |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Symbiotec Pharmalab IPO Peer Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab | 19.10 | 19.00 | 184.69 | - | 9.48 | - | - |
| Concord Biotech | 24.78 | 24.78 | - | 61.07 | 14.00 | - | - |
| Divi's Laboratories | 96.75 | 96.75 | 631.00 | 87.80 | 16.50 | 13.46 | - |
| Cohance Lifesciences | 4.69 | 4.68 | - | 95.02 | 7.00 | - | - |
| Laurus Labs | 16.47 | 16.45 | - | 109.36 | 16.80 | - | - |
Quick Info
| Sector | pharmaceutical and biotechnology |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹6,244.43 Cr |
Important Dates
| IPO Open | Aug 24, 2026 |
| IPO Close | Aug 27, 2026 |
| Allotment Date | Aug 28, 2026 |
| Credit to Demat | Aug 31, 2026 |
| Listing Date | Tentative: Sep 01, 2026 |
Lead Manager(s)
JM Financial Ltd.
Registrar
Description
- IPO Type: Book build issue aggregating to ₹1,757.00 crores.
- Issue Structure: A combination of fresh issue of 15.21 lakh shares aggregating to ₹150.00 crores and offer for sale of 1.63 crore shares aggregating to ₹1,607.00 crores.
- IPO Dates: The issue opened on August 24, 2026 and closed on August 27, 2026.
- Allotment Date: The allotment is expected to be finalized on August 28, 2026.
- Listing Details: The shares are proposed to be listed on both NSE and BSE on September 1, 2026.
- Retail Investment Requirement: Minimum 1 lot (15 shares) amounting to approximately ₹14,820 (at the upper price band).
- Employee Reservation: The issue includes a reservation of up to 33,408 shares for employees, offered at a ₹90 discount to the issue price.
- Issue Price Band: ₹938 to ₹988 per equity share.
- Lot Size: 15 shares per lot.
This IPO offers investors an opportunity to participate in the pharmaceutical sector through a combination of a fresh issue of shares and an offer for sale by existing shareholders.